Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Lipids in Health and Disease
|
September 3, 2015
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
Richard L Dunbar, Stephen J Nicholls, Kevin C Maki, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 6, 2019
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
Dirk Müller-Wieland, Daniel J Rader, Patrick M Moriarty, et al.
The American Journal of Cardiology
|
July 26, 2014
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)
Daniel Gaudet, Dean J Kereiakes, James M McKenney, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 8, 2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study
Eli M Roth, James M McKenney, Maureen T Kelly, et al.
Cardiovascular Drugs and Therapy
|
October 19, 2010
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study
Eli M Roth, Robert S Rosenson, Dawn M Carlson, et al.
International Journal of Cardiology
|
July 20, 2014
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial
Eli M Roth, Marja-Riitta Taskinen, Henry N Ginsberg, et al.
Lipids in Health and Disease
|
February 14, 2016
Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
Peter P Toth, Sara C Hamon, Steven R Jones, et al.
Journal of Clinical Lipidology
|
September 15, 2020
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
Eli M Roth, John J P Kastelein, Christopher P Cannon, et al.
Journal of Clinical Lipidology
|
November 12, 2019
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
Jennifer G Robinson, Michel Farnier, John J P Kastelein, et al.
European Heart Journal
|
March 7, 2014
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
Evan A Stein, Robert P Giugliano, Michael J Koren, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Lipids in Health and Disease
|
September 3, 2015
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
Richard L Dunbar, Stephen J Nicholls, Kevin C Maki, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 6, 2019
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
Dirk Müller-Wieland, Daniel J Rader, Patrick M Moriarty, et al.
The American Journal of Cardiology
|
July 26, 2014
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)
Daniel Gaudet, Dean J Kereiakes, James M McKenney, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 8, 2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study
Eli M Roth, James M McKenney, Maureen T Kelly, et al.
Cardiovascular Drugs and Therapy
|
October 19, 2010
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study
Eli M Roth, Robert S Rosenson, Dawn M Carlson, et al.
International Journal of Cardiology
|
July 20, 2014
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial
Eli M Roth, Marja-Riitta Taskinen, Henry N Ginsberg, et al.
Lipids in Health and Disease
|
February 14, 2016
Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
Peter P Toth, Sara C Hamon, Steven R Jones, et al.
Journal of Clinical Lipidology
|
September 15, 2020
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
Eli M Roth, John J P Kastelein, Christopher P Cannon, et al.
Journal of Clinical Lipidology
|
November 12, 2019
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
Jennifer G Robinson, Michel Farnier, John J P Kastelein, et al.
European Heart Journal
|
March 7, 2014
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
Evan A Stein, Robert P Giugliano, Michael J Koren, et al.
Page
of 4